Published • loading... • Updated
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
In 413 patients, the combination cut the risk of progression or death versus pembrolizumab alone and was also published in The Lancet.
- Yesterday at the ASCO Annual Meeting in Chicago, researchers presented Phase III OptiTROP-Lung05 results showing sac-TMT combined with pembrolizumab significantly improves progression-free survival in first-line non-small cell lung cancer patients.
- Developed by Sichuan Kelun-Biotech Biopharmaceutical, the TROP2 ADC sac-TMT uses a unique bifunctional linker to maximize payload delivery, offering a potential new 'ADC+IO' synergistic strategy for PD-L1 positive advanced NSCLC.
- In the 413-patient study, the combination group achieved a 12-month progression-free survival rate of 62.4% versus 29.0% for pembrolizumab alone, with median PFS not reached versus 5.7 months for control.
- Professor Caicun Zhou from Shanghai East Hospital, Tongji University, called the results 'encouraging,' while simultaneous publication in The Lancet underscores the clinical and academic value of this first-line approach.
- With 17 ongoing global Phase III studies, sac-TMT has received six Breakthrough Therapy Designations and is undergoing priority review by the National Medical Products Administration for this indication.
Insights by Ground AI
32 Articles
32 Articles
LoudounTimes.com+31 Reposted by 31 other sources
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05,…
Coverage Details
Total News Sources32
Leaning Left6Leaning Right1Center16Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 26%
C 70%
Factuality
To view factuality data please Upgrade to Premium
